KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $144.8 million.

  • Esperion Therapeutics' Cash & Current Investments fell 36.12% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $437.9 million, marking a year-over-year decrease of 31.88%. This contributed to the annual value of $144.8 million for FY2024, which is 76.01% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Cash & Current Investments of $144.8 million as of FY2024, which was up 76.01% from $82.2 million recorded in FY2023.
  • Esperion Therapeutics' Cash & Current Investments' 5-year high stood at $305.0 million during FY2020, with a 5-year trough of $82.2 million in FY2023.
  • Over the past 3 years, Esperion Therapeutics' median Cash & Current Investments value was $144.8 million (recorded in 2024), while the average stood at $131.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 50.71% in 2023, then spiked by 76.01% in 2024.
  • Esperion Therapeutics' Cash & Current Investments (Yearly) stood at $305.0 million in 2020, then dropped by 14.96% to $259.3 million in 2021, then tumbled by 35.66% to $166.9 million in 2022, then tumbled by 50.71% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024.